首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MIP1b |
| Uniprot No | P13236 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-92aa |
| 氨基酸序列 | APMGSDPPTACCFSYTARKLPRNFVVDYYETSSLCSQPAVVFQTKRGKQV CADPSESWVQEYVYDLELN |
| 预测分子量 | 8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MIP-1β(CCL4)重组蛋白的3篇参考文献示例，包含文献名称、作者及摘要概述：
---
1. **文献名称**：*Production and Characterization of Recombinant Human Macrophage Inflammatory Protein-1β (MIP-1β/CCL4)*
**作者**：Smith, M. A. J. et al. (1991)
**摘要**：该研究描述在大肠杆菌系统中高效表达重组人MIP-1β，并通过色谱技术纯化。实验验证其趋化活性，证明其可特异性招募单核细胞和T淋巴细胞，为后续功能研究奠定基础。
2. **文献名称**：*Structural Analysis of CCL4 and Its Interaction with CCR5 Receptor*
**作者**：Wang, H. et al. (2003)
**摘要**：通过X射线晶体学解析重组MIP-1β的三维结构，并探究其与HIV共受体CCR5的结合机制，为开发基于趋化因子的抗病毒药物提供结构生物学依据。
3. **文献名称**：*Recombinant MIP-1β Modulates HIV-1 Infection in Primary CD4+ T Cells*
**作者**：Alkhatib, G. et al. (1997)
**摘要**：利用重组MIP-1β蛋白阻断HIV-1病毒对CCR5受体的利用，显著抑制病毒进入靶细胞，揭示其在HIV治疗中的潜在应用价值。
---
**注**：以上文献信息为示例性质，实际引用需根据具体研究内容核实作者、年份及期刊准确性。建议通过PubMed或Web of Science以关键词“recombinant MIP-1β”或“CCL4 expression”检索最新文献。
MIP-1β (macrophage inflammatory protein-1 beta), also known as CCL4. is a small chemokine belonging to the CC chemokine family. It plays a critical role in immune regulation by recruiting and activating leukocytes, particularly monocytes, macrophages, dendritic cells, and T lymphocytes, to sites of inflammation or infection. Structurally, it is an 8-10 kDa protein containing conserved cysteine residues that form disulfide bonds essential for its tertiary structure and receptor-binding activity. MIP-1β exerts its biological effects primarily through interaction with chemokine receptors CCR1. CCR5. and CCR8. triggering intracellular signaling pathways that regulate cell migration, adhesion, and inflammatory responses.
Recombinant MIP-1β protein is produced using genetic engineering techniques, typically expressed in prokaryotic (e.g., E. coli) or eukaryotic systems (e.g., mammalian cells) to ensure proper folding and post-translational modifications. The recombinant form retains native bioactivity and is widely used in research to study inflammatory diseases, HIV pathogenesis (as CCR5 is a co-receptor for viral entry), autoimmune disorders (e.g., rheumatoid arthritis), and cancer immunology. Its role in modulating immune cell infiltration makes it a potential therapeutic target or biomarker for disease progression. Purified recombinant MIP-1β is often utilized in vitro and in vivo to investigate chemotaxis mechanisms, immune cell communication, and the development of anti-inflammatory or antiviral agents. Quality control includes endotoxin testing and functional assays to validate receptor-binding capacity.
×
